AbsciNASDAQ: ABSI

VANCOUVER, Wash. and NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on July 1, 2024, the company granted a non-statutory stock option to purchase an aggregate of 613,000 shares of its common stock to Ms. Shelby Walker in connection with her employment as Absci's Chief Legal Officer. The inducement grant was previously approved by Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to Ms. Walker's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

ABSCI Corporation's stock experienced a significant increase in the last trading session, accompanied by above-average trading volume. However, the recent changes in earnings estimates may not lead to additional price growth in the short term.

Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here is how Absci Corporation (ABSI) and Novo Nordisk (NVO) have performed compared to their sector so far this year.

Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.

Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday.

VANCOUVER, Wash. and NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

Penny stocks are often defined as stocks trading under $5 per share, those with a very low price per share or market capitalization, and are generally higher-risk. Now, despite many such stocks certainly carrying a relatively high risk profile, this often is somewhat offset by higher potential returns.

OpenAI is stealing the spotlight as the definitive artificial-intelligence startup — for now. Backed by Microsoft Corp. MSFT, the progenitor of ChatGPT-4 has become the focus of the AI wave, but other AI startups are emerging in fields including healthcare, education and manufacturing.